elegans genome encodes AGE-1 adaptor protein (AAP-1), a single PI3K adaptor subunit, and a putative IRS homolog, i.e., the adaptor protein or insulin receptor substrate (IST-1) homolog ( Drosophila melanogaster ) shows powerful similarities to C
The placebo-controlled SURMOUNT-OSA trial evaluated Zepbound for the treatment of moderate to severe OSA in adults with obesity, without type 2 diabetes mellitus (T2DM)
Better control of inflammation may reduce interruptions to training caused by minor illnesses
In Phase III clinical trial data released last year, people on the highest dose of orforglipron lost, on average, 10% of their baseline body weight, compared to the 2.5% average weight loss seen in people taking a placebo
Most side effects are mild and improve as your body adjusts, especially during dose increases
This approach, paired with lifestyle medicine, may support: Stable glucose and lipid metabolism Reduction of chronic inflammation and oxidative burden Preservation of lean muscle mass when combined with protein and resistance training Cognitive clarity and emotional regulation via improved central insulin signaling When applied responsibly, microdosing could become a foundational tool in female longevity protocols aimed at preventing the metabolic-cognitive cascade that defines aging
